A 72-year-old man presented with a 6-month history of systemic edema. Hyperpigmentation, hemangioma, pleural effusion, IgG-kappa-type monoclonal protein, high vascular endothelial growth factor values, renal failure, and nerve conduction study abnormalities were also present. Multiparameter flow cytometry (MFC) showed 0.2% neoplastic plasma cells (CD38-, CD56-, and kappa-positive; CD19-, CD27-, and lambdanegative) in the bone marrow leading to POEMS syndrome. Cases involving kappa-type POEMS syndrome are extremely rare. A kidney biopsy revealed membranous proliferative glomerulonephritis-like changes in our case. Lenalidomide-dexamethasone therapy improved the renal function. Detection of neoplastic plasma cells by MFC was useful for the accurate diagnosis and treatment evaluation.
Introduction
POEMS syndrome (Crow-Fukase syndrome, Takatsuki syndrome) is a rare plasma cell dyscrasia characterized by polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (1) (2) (3) . The various symptoms of this syndrome are thought to result from the high cytokinemia involving cytokines, such as vascular endothelial growth factor (VEGF), but the molecular pathology of the syndrome has not been sufficiently elucidated. In recent years, it has been reported that immunomodulatory drugs (IMiDs) targeting VEGF, such as thalidomide and lenalidomide, have good therapeutic effects for this condition (4) (5) (6) .
The usefulness of detecting minimal residual disease (MRD) by multiparameter flow cytometry (MFC) has been reported in determining the therapeutic effect after treatment of multiple myeloma (MM) (7) . However, the fraction of monoclonal plasma cells in POEMS syndrome is often small. Therefore, it is difficult to identify neoplastic plasma cells by conventional flow cytometry in patients with this syndrome (8) .
All cases of POEMS syndrome reported so far have had the lambda-type monoclonal protein, except for four cases previously reported in the literature. We herein report a rare case of POEMS syndrome with IgG-kappa-type monoclonal protein, wherein a small number of neoplastic plasma cells were identified by MFC, and a good therapeutic effect was achieved by lenalidomide-dexamethasone (Ld) therapy. lary tenderness, but absence of hypertrichosis ( Fig. 1) . A hematological examination showed a white blood cell count of 5.8×10 9 /L with a normal differential count, a hemoglobin concentration of 10.1 g/dL, and a platelet count of 56×10 9 / L. The patient was in renal failure, with a serum creatinine level of 1.30 mg/dL. Serum VEGF, plasma VEGF, and serum interleukin-6 (IL-6) concentrations were elevated to 1,790 pg/mL, 1,120 pg/mL, and 9.1 pg/mL, respectively. In addition, endocrine abnormalities, such as elevation of luteinizing hormone, follicle-stimulating hormone, and prolactin, were observed (Table 1) . IgG-kappa-type monoclonal protein was observed by serum protein immunofixation, but serum IgG levels were normal. A urinalysis revealed albuminuria, but Bence-Jones protein was not observed.
An ultrasound examination showed pericardial effusion of about 400 mL, but the ejection fraction was normal. Wholebody computed tomography showed pleural effusion and pelvic bone sclerosis but no lymphadenopathy, hepatomegaly, or splenomegaly ( Fig. 2) . Positron emission tomography did not reveal any tumorous accumulation. A nerve conduction study showed polyneuropathy with dominant axonal degeneration accompanied by a decrease in nerve conduction velocity, extension of distant latency, and reduction of compound muscle action potential. Bone marrow aspiration showed 1.2% plasma cells, sometimes associated with atypia ( Fig. 3A ). An increase was observed in the number of megakaryocytes (109.4/μL) without atypia. IgGkappa-type monoclonal protein was also recognized by immunofixation of bone marrow blood ( Fig. 3B ). MFC (Du-raClone, Beckman Coulter, Brea, USA; Table 2 ) showed 0.2% neoplastic plasma cells with kappa chains (Fig. 3C) . A percutaneous kidney biopsy revealed membranoproliferative glomerulonephritis (MPGN)-like changes, but there was no deposition of immunoglobulins or light chains ( Fig. 4) . Amyloidosis was not observed on a bone marrow biopsy, skin biopsy, renal biopsy, or intestinal biopsy.
Since the diagnostic criteria of the Mayo Clinic (9) were satisfied, we finally diagnosed the patient with POEMS syndrome. Because of anemia, thrombocytopenia, and Creactive protein positivity, overlap with Castleman's disease was considered. However, because there were no enlarged lymph nodes, we excluded Castleman's disease. The patient also met the diagnostic criteria for the recently proposed TAFRO syndrome as he tested positive for fluid retention, thrombocytopenia, high inflammatory response, megakaryocytic hyperplasia, and progressive kidney failure. However, our case showed the presence of monoclonal protein and an abnormality in the nerve conduction test, so TAFRO syndrome was excluded.
In order to avoid inducing peripheral neuropathy with thalidomide, we chose lenalidomide 10 mg/day and dexamethasone 20 mg/week (Ld) therapy. In accordance with our institutional regulations, all treatments in this case were provided with the approval of the institutional review board and the consent of the patient. Pleural effusion and limb pain quickly improved after treatment was started. In addition, we observed the recovery of the platelet counts, improvement of the renal function, and reduction of the inflammatory response. The treatment efficacy parameters, as evaluated by the Mayo Clinic criteria (10) after two courses of Ld therapy, were as follows: hematologic response, could not be evaluated; VEGF response, partial VEGF response (PRV); clinical response, clinical improvement (IC); and PET response, could not be evaluated. MFC showed a reduction in the fraction of neoplastic plasma cells, confirming the therapeutic effect ( Fig. 5 ). The patient was transferred to a hospital near his residence and continued to receive Ld therapy. The dexamethasone dose was reduced because he developed sleeplessness; however, his symptoms did not relapse after dose reduction. Plasma VEGF levels also did not 
Discussion
The detection of MRD has become very important in the treatment of hematological malignancies (11) . Generally, MFC is a method for detecting MRD by identifying tumorspecific surface antigens using antibodies labeled with four or more color fluorochromes. In the present case, MFC identified small amounts of neoplastic plasma cells, which are characteristic of POEMS syndrome. As shown in Table 3, it was observed that the surface antigen profile of 1  CD38  CD45  CD81  CD27  CD19  CD200 CD138  CD56  2  CD45  CD138  CD38  Lambda  CD56  CD19 Kappa neoplastic plasma cells in this case (CD27 negative, CD19 negative, CD56 positive, and CD81 diminished) was more similar to that of myeloma cells than to that of monoclonal gammopathy of undetermined significance (MGUS) (12) (13) (14) . This suggests that neoplastic plasma cells of POEMS syndrome (even in small numbers) are malignant. It has been reported that CD27, which was decreased in the present case, does not decrease in cases of MGUS but does decrease in cases of MM (12, 15) . Negative CD27 is considered to indicate a poor prognosis in MM (15, 16) . However, the relationship between the surface antigen profile of neoplastic plasma cells and the therapeutic reactivity/ prognosis in POEMS syndrome has not been clarified, so further research is necessary. In addition, in most cases of POEMS syndrome, the proportion of neoplastic plasma cells is lower than that in MM. Therefore, MRD detection by MFC seems to be very useful for the diagnosis and followup of POEMS syndrome, in addition to assessments of the clinical symptoms and VEGF values.
Since serum VEGF is strongly influenced by the level of platelets, it is recommended that plasma VEGF levels be used to evaluate the therapeutic effect (10, 17) . Indeed, serum VEGF levels have been reported to be over 10 times higher than plasma VEGF levels because of the release of VEGF from activated or aggregated platelets (18) . Therefore, we used plasma VEGF levels to evaluate the therapeu-tic effect in our patient with thrombocytopenia.
Almost all patients with POEMS syndrome have the lambda-type monoclonal protein (19) (20) (21) . This is because monoclonal proteins have a specific V lambda subfamily gene that can cause high cytokinemia involving cytokines, such as VEGF via some signals (22) . However, the mechanism has not been fully elucidated. In contrast, POEMS syndrome with kappa-type monoclonal protein is very rare. Table 4 shows the details of five POEMS syndrome cases with kappa-type monoclonal protein, including our own (23) (24) (25) (26) . All patients showed some endocrine abnormality. Interestingly, renal failure was a complication in three cases, including our own. It has been reported that about 20% of PO-EMS syndrome cases have associated renal dysfunction (27) . In our earlier study, we reported the clinicopathological features of 52 patients with POEMS syndrome with renal complications. Over half of the patients had renal dysfunction with serum creatinine >1.5 mg/dL, and 10% of the patients needed renal replacement therapy. The histological findings of the kidney in POEMS syndrome frequently include MPGN-like glomerular changes, such as glomerular swelling, mesangial proliferation, mesangiolysis, and endothelial and mesangial cell enlargement (28) . These glomerular changes are thought to be caused by cytokines, such as VEGF and IL-6 (29) . Nephropathy in POEMS syndrome is significantly improved by treatment with new agents, including lenalidomide, compared to treatment without these agents (27) . In our case, Ld therapy improved the renal function as plasma VEGF levels decreased. For patients with renal dysfunction, it is necessary to reduce the dose of lenalidomide in order to prevent hematologic toxicity and maintain optimal plasma concentrations (30) . Lenalidomide can be safely used in patients with POEMS syndrome with renal dysfunction.
In conclusion, our case suggested that identification of neoplastic plasma cells by MFC is important for obtaining a proper diagnosis and enacting treatment of POEMS syndrome. In the future, MFC will be essential for the treatment of this syndrome. Ld therapy might be effective in cases of POEMS syndrome for reducing VEGF levels. It is also important to clarify the cause of kidney dysfunction by a renal biopsy in POEMS syndrome patients with renal failure. Furthermore, since POEMS syndrome with kappa-type monoclonal protein is very rare, it is necessary to increase our knowledge about its clinical presentation and therapeutic reactivity. 
